Krilogy Financial LLC Acquires 8,801 Shares of Repligen Corporation $RGEN

Krilogy Financial LLC boosted its stake in Repligen Corporation (NASDAQ:RGEN) by 81.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,557 shares of the biotechnology company’s stock after purchasing an additional 8,801 shares during the period. Krilogy Financial LLC’s holdings in Repligen were worth $2,485,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. NewEdge Wealth LLC lifted its holdings in Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after buying an additional 75 shares during the period. UMB Bank n.a. increased its stake in shares of Repligen by 13.8% in the fourth quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 92 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after acquiring an additional 100 shares during the last quarter. Coldstream Capital Management Inc. raised its position in shares of Repligen by 5.3% during the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 104 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on RGEN. HC Wainwright upped their target price on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. JPMorgan Chase & Co. dropped their price target on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Wells Fargo & Company reduced their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Trading Up 9.5%

NASDAQ RGEN opened at $138.40 on Thursday. The business has a 50 day simple moving average of $122.25 and a 200 day simple moving average of $135.60. Repligen Corporation has a one year low of $100.99 and a one year high of $175.77. The stock has a market capitalization of $7.81 billion, a P/E ratio of 153.78, a P/E/G ratio of 2.43 and a beta of 1.09. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.78.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. The firm had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company’s revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Research analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.